• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特定的基因组畸变可预测生存率,但在透明细胞肾细胞癌中,癌症热点区域的突变率较低。

Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.

作者信息

Köhn Linda, Svenson Ulrika, Ljungberg Börje, Roos Göran

机构信息

*Department of Medical Biosciences/Pathology †Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

出版信息

Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):334-42. doi: 10.1097/PAI.0000000000000087.

DOI:10.1097/PAI.0000000000000087
PMID:24992170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4431677/
Abstract

Detailed genetic profiling of clear cell renal cell carcinoma (ccRCC) has revealed genomic regions commonly affected by structural changes and a general genetic heterogeneity. VHL and PBRM1, both located at chromosome 3p, are 2 major genes mutated at high frequency but apart from these aberrations, the mutational landscape in ccRCC is largely undefined. Potential prognostic information given by the genomic changes appears to depend on the particular cohort studied. We analyzed a Swedish ccRCC cohort of 74 patients and found common changes (loss or gain occurring in >20% of the tumors) in 12 chromosomal regions (1p, 3p, 3q, 5q, 6q, 7p, 7q 8p, 9p, 9q, 10q, and 14q). A poor outcome was associated with gain of 7q and losses on 9p, 9q, and 14q. These aberrations were more frequent in metastasized tumors, suggesting alterations of genes important for tumor progression. Sequencing of 48 genes implicated in cancer revealed that only VHL, TP53, and PTEN were mutated at a noticeable frequency (51%, 9%, and 9%, respectively). Shorter relative telomere length (RTL) has been associated with loss of specific chromosomal regions in ccRCC tumors, but we could not verify this finding. However, a significantly lower tumor/nontumor (T/N) RTL ratio was detected for tumors with losses in 4q or 9p. In conclusion, poor outcome in ccRCC was associated with gain of 7q and loss on 9p, 9q, and 14q, whereas the mutation rate overall was low in a screen of cancer-associated genes.

摘要

透明细胞肾细胞癌(ccRCC)的详细基因图谱分析揭示了通常受结构变化影响的基因组区域以及普遍存在的基因异质性。VHL和PBRM1均位于3号染色体p臂,是两个高频突变的主要基因,但除了这些畸变外,ccRCC的突变图谱在很大程度上尚不明确。基因组变化所提供的潜在预后信息似乎取决于所研究的特定队列。我们分析了一个由74例患者组成的瑞典ccRCC队列,发现在12个染色体区域(1p、3p、3q、5q、6q、7p、7q、8p、9p、9q、10q和14q)存在常见变化(在>20%的肿瘤中出现缺失或增益)。不良预后与7q增益以及9p、9q和14q缺失相关。这些畸变在转移瘤中更为常见,提示对肿瘤进展重要的基因发生了改变。对48个与癌症相关基因的测序显示,只有VHL、TP53和PTEN以显著频率发生突变(分别为51%、9%和9%)。较短的相对端粒长度(RTL)与ccRCC肿瘤中特定染色体区域的缺失有关,但我们无法证实这一发现。然而,对于在4q或9p有缺失的肿瘤,检测到肿瘤/非肿瘤(T/N)RTL比率显著较低。总之,ccRCC的不良预后与7q增益以及9p、9q和14q缺失相关,而在癌症相关基因筛查中总体突变率较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/8cbe2bb25557/pai-23-334-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/c17af794b051/pai-23-334-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/0e5054a87dae/pai-23-334-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/8cbe2bb25557/pai-23-334-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/c17af794b051/pai-23-334-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/0e5054a87dae/pai-23-334-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f20/4431677/8cbe2bb25557/pai-23-334-g008.jpg

相似文献

1
Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.特定的基因组畸变可预测生存率,但在透明细胞肾细胞癌中,癌症热点区域的突变率较低。
Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):334-42. doi: 10.1097/PAI.0000000000000087.
2
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.染色体 3p 和 14q 的缺失从分子水平上对透明细胞肾细胞癌进行了分类。
Cancer. 2013 Apr 15;119(8):1547-54. doi: 10.1002/cncr.27947. Epub 2013 Jan 18.
3
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.冯·希佩尔-林道病相关及散发性肾透明细胞癌中的基因表达模式和拷贝数改变
Cancer Res. 2009 Jun 1;69(11):4674-81. doi: 10.1158/0008-5472.CAN-09-0146.
4
Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.巴西患者肾透明细胞癌中的体细胞拷贝数改变及相关基因
Int J Mol Sci. 2021 Feb 25;22(5):2265. doi: 10.3390/ijms22052265.
5
Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology.肾细胞癌中的基因组改变与不稳定性及其与肿瘤病理学的关系。
Cancer Res. 1995 Dec 15;55(24):6189-95.
6
Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.原发性透明细胞肾细胞癌的突变特征可预测复发风险和辅助免疫检查点抑制治疗的潜在获益人群。
F1000Res. 2024 Jun 14;12:918. doi: 10.12688/f1000research.136087.2. eCollection 2023.
7
PBRM1 and BAP1 as novel targets for renal cell carcinoma.PBRM1 和 BAP1 作为肾细胞癌的新靶点。
Cancer J. 2013 Jul-Aug;19(4):324-32. doi: 10.1097/PPO.0b013e3182a102d1.
8
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.细胞遗传学特征可预测透明细胞肾细胞癌患者的预后。
J Clin Oncol. 2009 Feb 10;27(5):746-53. doi: 10.1200/JCO.2007.15.8345. Epub 2009 Jan 5.
9
Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.应用数字多重连接依赖探针扩增技术预测透明细胞肾细胞癌转移。
Cancer Sci. 2022 Jan;113(1):297-307. doi: 10.1111/cas.15170. Epub 2021 Nov 3.
10
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma.克隆结构可预测肾透明细胞癌的临床结局。
Nat Commun. 2019 Mar 18;10(1):1245. doi: 10.1038/s41467-019-09241-7.

引用本文的文献

1
DNA methylation expression patterns predict outcome of clear cell renal cell carcinoma.DNA甲基化表达模式可预测透明细胞肾细胞癌的预后。
Discov Oncol. 2025 May 26;16(1):934. doi: 10.1007/s12672-025-02764-0.
2
A Review of the Paradigmatic Role of Adipose Tissue in Renal Cancer: Fat Measurement and Tumor Behavior Features.脂肪组织在肾癌中的范式作用综述:脂肪测量与肿瘤行为特征
Cancers (Basel). 2024 Apr 27;16(9):1697. doi: 10.3390/cancers16091697.
3
Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies.

本文引用的文献

1
Comprehensive molecular characterization of clear cell renal cell carcinoma.透明细胞肾细胞癌的全面分子特征分析。
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23.
2
Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.散发性甲状旁腺腺瘤中细胞周期蛋白依赖性激酶抑制剂基因 CDKN1A、CDKN2B 和 CDKN2C 的种系和体细胞突变。
Horm Cancer. 2013 Oct;4(5):301-7. doi: 10.1007/s12672-013-0147-9. Epub 2013 May 29.
3
Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma.
透明细胞肾细胞癌治疗的最新进展:新型生物标志物与靶向治疗
Cancers (Basel). 2023 Jun 16;15(12):3207. doi: 10.3390/cancers15123207.
4
Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.应用数字多重连接依赖探针扩增技术预测透明细胞肾细胞癌转移。
Cancer Sci. 2022 Jan;113(1):297-307. doi: 10.1111/cas.15170. Epub 2021 Nov 3.
5
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.抗血管生成与免疫疗法:肾细胞癌个体化治疗的新范式
J Clin Med. 2020 May 24;9(5):1594. doi: 10.3390/jcm9051594.
6
DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.DNA 甲基化与非转移性透明细胞肾细胞癌的生存相关。
BMC Cancer. 2019 Jan 14;19(1):65. doi: 10.1186/s12885-019-5291-3.
7
Genomic Alteration in Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Inferred from Karyotyping, Molecular Cytogenetics, and Array Comparative Genomic Hybridization.通过核型分析、分子细胞遗传学和阵列比较基因组杂交推断头颈部鳞状细胞癌(HNSCC)细胞系中的基因组改变
PLoS One. 2016 Aug 8;11(8):e0160901. doi: 10.1371/journal.pone.0160901. eCollection 2016.
8
DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).DNA甲基化状态决定了包括透明细胞肾细胞癌(ccRCC)患者生存率在内的临床病理参数。
Tumour Biol. 2016 Aug;37(8):10219-28. doi: 10.1007/s13277-016-4893-5. Epub 2016 Jan 30.
多层次全基因组分析揭示透明细胞肾细胞癌的候选生物标志物。
Cancer Res. 2012 Oct 15;72(20):5273-84. doi: 10.1158/0008-5472.CAN-12-0656. Epub 2012 Aug 27.
4
BAP1 loss defines a new class of renal cell carcinoma.BAP1 缺失定义了一类新的肾细胞癌。
Nat Genet. 2012 Jun 10;44(7):751-9. doi: 10.1038/ng.2323.
5
State of the science: an update on renal cell carcinoma.科学现状:肾细胞癌的最新进展。
Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25.
6
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development.在透明细胞肾细胞癌肿瘤中进行靶向外显子测序表明,染色质调控异常是 ccRCC 发展中的关键步骤。
Hum Mutat. 2012 Jul;33(7):1059-62. doi: 10.1002/humu.22090. Epub 2012 Apr 30.
7
Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.FGFR3 基因突变激活:与肾细胞癌的发生无关。
J Cancer Res Clin Oncol. 2012 Feb;138(2):359-61. doi: 10.1007/s00432-011-1130-x. Epub 2011 Dec 28.
8
Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma.鉴定与透明细胞肾细胞癌转移和癌症特异性生存相关的基因组改变。
J Urol. 2011 Nov;186(5):2078-83. doi: 10.1016/j.juro.2011.06.050. Epub 2011 Sep 23.
9
Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.14q 染色体缺失定义了与预后不良相关的透明细胞肾细胞癌的一种分子亚型。
Mod Pathol. 2011 Nov;24(11):1470-9. doi: 10.1038/modpathol.2011.107. Epub 2011 Jul 1.
10
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.外显子组测序鉴定出肾癌中 SWI/SNF 复合物基因 PBRM1 的高频突变。
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.